InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,152.00
(
-0.06%
)
Post# of 252199
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: oc631 post# 169184

Saturday, 11/02/2013 3:20:29 PM

Saturday, November 02, 2013 3:20:29 PM

Post# of 252199

It's just strange announcing only GT2 results in the PR considering it's a GT2/GT3 study.





The GT3 SVR rates are listed outside the LONESTAR-2 title heading within the PR. Twelve-week (n=24), Sofo/PegRiba SVR rates of 83% puts the option within the same range as 24-weeks of oral.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up